menu
    • menu
    [{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Fulzerasib","moa":"Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GenFleet Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"GenFleet Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Guangdong Association of Clinical Trials","sponsor":"Innovent Biologics | Mabpharm","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Fulzerasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase II","graph3":"Guangdong Association of Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Guangdong Association of Clinical Trials \/ Innovent Biologics | Mabpharm","highestDevelopmentStatusID":"8","companyTruncated":"Guangdong Association of Clinical Trials \/ Innovent Biologics | Mabpharm"}]

    Find Clinical Drug Pipeline Developments & Deals for Fulzerasib

    Menu

    Fulzerasib

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Guangdong Association of Clinical Trials

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed

                            Guangdong Association of Clinical Trials

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fulzerasib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Innovent Biologics | Mabpharm

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation

                            Details : Fulzerasib is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 30, 2025

                            Lead Product(s) : Fulzerasib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Innovent Biologics | Mabpharm

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            GenFleet Therapeutics

                            China arrow
                            AllPack Indonesia
                            Not Confirmed

                            GenFleet Therapeutics

                            China arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fulzerasib

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            GenFleet Announces KRAS G12C Inhibitor Approval in China for Lung Cancer

                            Details : Dupert (fulzerasib) is a novel small molecule KRAS G12C inhibitor, which is indicated for the treatment of patients with advanced solid tumors with KRAS G12C mutations.

                            Product Name : Dupert

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 23, 2024

                            Lead Product(s) : Fulzerasib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth